Definium Therapeutics, Inc. Announces Proposed Public Offering (opens original article in a new tab)

Definium Therapeutics, Inc. plans to conduct a $500 million public offering of common shares and pre-funded warrants, with an option for underwriters to purchase additional shares, aiming to fund research, development, and commercialization efforts.

• Definium Therapeutics plans to offer $500 million in common shares and pre-funded warrants in a public offering
• The company may also sell an additional $75 million in shares under an underwriters' option
• Proceeds will fund R&D, commercialization prep for DT120 ODT, and general corporate use
• J.P. Morgan, Jefferies, and others are leading the offering underwriters